Meltzer L T, Caprathe B W, Christoffersen C L, Corbin A E, Jaen J C, Ninteman F W, Pugsley T A, Serpa K A, Shih Y H, Whetzel S Z
Department of Pharmacology, Parke-Davis Pharmaceutical Research, Warner-Lambert Company, Ann Arbor, Michigan.
J Pharmacol Exp Ther. 1993 Sep;266(3):1177-89.
(+/-)-PD 128483, ((+/-)-4,5,5a,6,7,8-hexahydro-6-methylthiazolo[4,5-f]-quinolin+ ++-2-amine, maleate (1:1)), is a racemic compound that is a p.o. active dopamine (DA) partial agonist that has DA autoreceptor agonist effects and displays antipsychoticlike activity in preclinical tests. In in vitro receptor binding assays, (+/-)-PD 128483 and its enantiomers bound selectively to DA D-2 receptors vs. DA D-1 receptors and showed no affinity for adrenergic alpha-1 or serotonin1A receptors, but had affinity for adrenergic alpha-2 receptors. In tests of DA agonist effects, including reversal of the tau-butyrolactone-stimulated increase in brain dopa synthesis in striatum and inhibition of DA neuronal firing, the rank order of efficacy was (+)-PD 128483 > (+/-)-PD 128483 > (-)-PD 128483. (+/-)-PD 128483 and (+)-PD 128483 inhibited, whereas (-)-PD 128483 increased, brain DA synthesis in normal rats. (+/-)-PD 128483 and (-)-PD 128483 inhibited spontaneous locomotion in rats and did not produce locomotor stimulation or stereotypies. In contrast, (+)-PD 128483 inhibited locomotor activity at low doses, but at relatively high doses increased locomotion and induced stereotypy in rats. (-)-PD 128483 consistently inhibited Sidman avoidance responding in squirrel monkeys. (+/-)-PD 128483 inhibited Sidman avoidance responding in one group of monkeys, but had minimal effects in another group. (+)-PD 128483 did not inhibit avoidance responding. In squirrel or cebus monkeys sensitized to the acute dystonic effects of haloperidol, only (-)-PD 128483 induced extrapyramidal dysfunction. These results indicate that (+/-)-PD 128483 is a DA partial agonist which produces DA autoreceptor agonist effects and has a preclinical behavioral profile suggestive of antipsychotic activity.
(±)-PD 128483,((±)-4,5,5a,6,7,8-六氢-6-甲基噻唑并[4,5-f]喹啉-2-胺,马来酸盐(1:1)),是一种外消旋化合物,是一种口服活性多巴胺(DA)部分激动剂,具有DA自身受体激动剂作用,并在临床前试验中表现出抗精神病样活性。在体外受体结合试验中,(±)-PD 128483及其对映体相对于DA D-1受体选择性地与DA D-2受体结合,对肾上腺素能α-1或5-羟色胺1A受体无亲和力,但对肾上腺素能α-2受体有亲和力。在DA激动剂作用的试验中,包括逆转纹状体中tau-丁内酯刺激的脑多巴合成增加和抑制DA神经元放电,效力的顺序为(+)-PD 128483 >(±)-PD 128483 >(-)-PD 128483。(±)-PD 128483和(+)-PD 128483抑制正常大鼠脑DA的合成,而(-)-PD 128483则增加其合成。(±)-PD 128483和(-)-PD 128483抑制大鼠的自发运动,且不产生运动刺激或刻板行为。相比之下,(+)-PD 128483在低剂量时抑制运动活动,但在相对高剂量时增加大鼠的运动并诱导刻板行为。(-)-PD 128483持续抑制松鼠猴的Sidman回避反应。(±)-PD 128483在一组猴子中抑制Sidman回避反应,但在另一组中作用极小。(+)-PD 128483不抑制回避反应。在对氟哌啶醇的急性肌张力障碍作用敏感的松鼠猴或卷尾猴中,只有(-)-PD 128483诱导锥体外系功能障碍。这些结果表明,(±)-PD 128483是一种DA部分激动剂,产生DA自身受体激动剂作用,并具有提示抗精神病活性的临床前行为特征。